Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.23 USD | +0.06% |
|
+1.77% | +48.79% |
09/05 | Transcript : Phibro Animal Health Corporation, Q3 2024 Earnings Call, May 09, 2024 | |
08/05 | Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q3 EPS $0.31, vs. Street Est of $0.29 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.21 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+48.79% | 698M | C | ||
+22.35% | 9.01B | B- | ||
+23.12% | 3.64B | B- | ||
-4.17% | 3.06B | B- | ||
+12.67% | 1.65B | - | ||
-4.88% | 1.23B | - | ||
-30.18% | 1.16B | B | ||
-31.11% | 1.15B | C- | ||
-23.45% | 999M | - | ||
-11.41% | 926M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PAHC Stock
- Ratings Phibro Animal Health Corporation